As Asian markets navigate a complex economic landscape marked by global uncertainties and regional developments, investors are increasingly turning their attention to under-the-radar opportunities. Penny stocks, though an older term, still capture the essence of investing in smaller or newer companies that may offer significant growth potential at lower price points. By focusing on those with strong financial health and clear growth prospects, investors can uncover hidden gems that might provide both stability and upside potential.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| Food Moments (SET:FM) | THB3.80 | THB3.75B | ✅ 4 ⚠️ 0 View Analysis > |
| JBM (Healthcare) (SEHK:2161) | HK$2.99 | HK$2.43B | ✅ 3 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.51 | HK$933.97M | ✅ 4 ⚠️ 1 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.71 | HK$2.25B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.33 | SGD539.03M | ✅ 4 ⚠️ 1 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.78 | THB2.87B | ✅ 3 ⚠️ 3 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.38 | SGD13.3B | ✅ 5 ⚠️ 1 View Analysis > |
| Anton Oilfield Services Group (SEHK:3337) | HK$1.16 | HK$3.35B | ✅ 4 ⚠️ 1 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$0.97 | NZ$138.07M | ✅ 2 ⚠️ 5 View Analysis > |
| Rojana Industrial Park (SET:ROJNA) | THB4.80 | THB9.7B | ✅ 3 ⚠️ 3 View Analysis > |
Click here to see the full list of 957 stocks from our Asian Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Brii Biosciences (SEHK:2137)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Brii Biosciences Limited develops therapies for infectious and central nervous system diseases in China and the United States, with a market cap of HK$1.66 billion.
Operations: The company generates CN¥33.83 million in revenue from its biotechnology startups segment.
Market Cap: HK$1.66B
Brii Biosciences, with a market cap of HK$1.66 billion, is pre-revenue, generating CN¥33.83 million in revenue from its biotechnology startups segment. Despite being unprofitable with a net loss of CN¥148.07 million for H1 2025, the company has improved its financial health by reducing losses significantly over five years and maintaining no debt. Its short-term assets of CN¥2.1 billion comfortably cover both short and long-term liabilities, providing a cash runway exceeding three years even if free cash flow grows modestly. Recent inclusion in the S&P Global BMI Index may enhance visibility among investors interested in Asian penny stocks.
- Unlock comprehensive insights into our analysis of Brii Biosciences stock in this financial health report.
- Learn about Brii Biosciences' future growth trajectory here.
AGTech Holdings (SEHK:8279)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: AGTech Holdings Limited is an investment holding company offering digital banking and payment services in Mainland China, Macau, and internationally, with a market cap of approximately HK$2.65 billion.
Operations: The company's revenue is primarily derived from its Electronic Payment and Related Services segment at HK$307.26 million, followed by Lottery Operation at HK$239.95 million and Banking Business at HK$67.76 million.
Market Cap: HK$2.65B
AGTech Holdings, with a market cap of HK$2.65 billion, remains unprofitable but has made strides by reducing losses over the past five years and maintaining a debt-free status. The company’s short-term assets of HK$4.2 billion comfortably cover its liabilities, ensuring a cash runway exceeding three years even with shrinking free cash flow. Recent strategic alliances, such as the cooperation agreement with China Arts and Entertainment Group Ltd., aim to leverage cultural development strategies in Macau, potentially enhancing its operational scope without immediate financial strain from winding up non-operational joint ventures like Asia Gaming Technologies Limited.
- Click here to discover the nuances of AGTech Holdings with our detailed analytical financial health report.
- Explore historical data to track AGTech Holdings' performance over time in our past results report.
Raffles Medical Group (SGX:BSL)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Raffles Medical Group Ltd offers integrated private healthcare services across Singapore, Greater China, Vietnam, Cambodia, and Japan with a market cap of SGD1.85 billion.
Operations: The company's revenue segments include Hospital Services at SGD352.07 million, Insurance Services at SGD186.63 million, and Healthcare Services at SGD295.96 million, with additional contributions from Investment Holdings amounting to SGD44.46 million.
Market Cap: SGD1.85B
Raffles Medical Group, with a market cap of SGD1.85 billion, demonstrates financial stability through its diversified revenue streams across healthcare and insurance services. Recent executive changes, including the appointment of Ms. Woo Yeng Yeng as CFO, bring seasoned leadership to enhance financial strategy and governance. The company’s strategic share repurchase program indicates confidence in its valuation while maintaining robust cash flow coverage for debt obligations. Despite stable earnings growth over the past year at 4.5%, which is below industry averages, Raffles Medical remains profitable with well-managed liabilities and a strong management team guiding future operations.
- Dive into the specifics of Raffles Medical Group here with our thorough balance sheet health report.
- Understand Raffles Medical Group's earnings outlook by examining our growth report.
Make It Happen
- Gain an insight into the universe of 957 Asian Penny Stocks by clicking here.
- Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 34 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Brii Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com